IPCA Laboratories Ltd
NSE:IPCALAB

Watchlist Manager
IPCA Laboratories Ltd Logo
IPCA Laboratories Ltd
NSE:IPCALAB
Watchlist
Price: 1 581.7 INR -0.26% Market Closed
Market Cap: 401.3B INR
Have any thoughts about
IPCA Laboratories Ltd?
Write Note

IPCA Laboratories Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IPCA Laboratories Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
IPCA Laboratories Ltd
NSE:IPCALAB
Operating Income
â‚ą11.3B
CAGR 3-Years
-1%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Operating Income
â‚ą66.3B
CAGR 3-Years
27%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Operating Income
â‚ą56.2B
CAGR 3-Years
17%
CAGR 5-Years
21%
CAGR 10-Years
14%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Operating Income
â‚ą112.5B
CAGR 3-Years
13%
CAGR 5-Years
17%
CAGR 10-Years
4%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Operating Income
â‚ą27.8B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
10%
M
Mankind Pharma Ltd
NSE:MANKIND
Operating Income
â‚ą21.5B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

IPCA Laboratories Ltd
Glance View

Market Cap
401.3B INR
Industry
Pharmaceuticals

In the bustling corridors of the global pharmaceutical industry, IPCA Laboratories Ltd. stands as a formidable presence, deeply rooted in its commitment to innovative healthcare solutions. Established with a mission to enhance patient well-being, IPCA has grown from a modest formulation company in India into a multinational endeavor, celebrated for its prowess in the realms of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. This vertically integrated company meticulously controls every element of its production chain, securing its position as a trusted supplier to some of the world's leading pharmaceutical giants. IPCA's robust portfolio includes a wide array of therapeutic segments, from antimalarials and analgesics to antihypertensives and nutraceuticals, showcasing its versatility and comprehensive grasp over diverse medical needs. What sets IPCA apart in the crowded pharmaceutical landscape is its strategic blend of cutting-edge research, efficient manufacturing practices, and a global distribution network. The company invests significantly in research and development, channeling innovation into its drug development processes to sustain its competitive edge. Enhanced production capabilities at its state-of-the-art facilities ensure that IPCA not only meets stringent international standards but also operates at optimal cost efficiency. This enables the company to leverage economies of scale, thereby maximizing profitability. By exporting to over 100 countries and employing a robust marketing strategy, IPCA ensures its products have a wide reach across developed and emerging markets. Thus, through its integrated approach to drug development and distribution, IPCA Laboratories continues to cultivate a steady stream of revenue while contributing substantially to global healthcare.

IPCALAB Intrinsic Value
1 236.48 INR
Overvaluation 22%
Intrinsic Value
Price

See Also

What is IPCA Laboratories Ltd's Operating Income?
Operating Income
11.3B INR

Based on the financial report for Sep 30, 2024, IPCA Laboratories Ltd's Operating Income amounts to 11.3B INR.

What is IPCA Laboratories Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
11%

Over the last year, the Operating Income growth was 55%. The average annual Operating Income growth rates for IPCA Laboratories Ltd have been -1% over the past three years , 11% over the past five years .

Back to Top